Can I Take Ashwagandha with Farxiga (Dapagliflozin)?

What Farxiga (Dapagliflozin) Actually Does

Dapagliflozin selectively blocks the sodium-glucose cotransporter 2 (SGLT2) protein in the proximal renal tubule, forcing roughly 70 grams of glucose per day out through the urine in patients with adequate kidney function. [1] Because glucose excretion is kidney-dependent, dapagliflozin's efficacy starts to fall when eGFR drops below 45 mL/min/1.73 m2 for glycemic goals.

Approved Indications

The FDA has approved dapagliflozin for three distinct conditions:

• Type 2 diabetes (since 2014): reduces HbA1c by approximately 0.9 percentage points as monotherapy [2]
• Heart failure with reduced ejection fraction (since 2020): the DAPA-HF trial (N=4,744) showed a 26% relative risk reduction in the composite of worsening heart failure or cardiovascular death vs. Placebo [3]
• Chronic kidney disease (since 2021): DAPA-CKD (N=4,304) demonstrated a 39% relative reduction in a composite renal and cardiovascular outcome [4]

How the Drug Is Metabolized

Dapagliflozin is metabolized primarily by UGT1A9 (uridine 5-diphospho-glucuronosyltransferase 1A9) in the liver and kidney, not by the cytochrome P450 system. [1] This is a critical fact when assessing supplement interactions. Most herb-drug interactions run through CYP3A4, CYP2D6, or P-glycoprotein. Because dapagliflozin sits outside those pathways, a strict pharmacokinetic interaction with ashwagandha is unlikely but cannot be entirely excluded based on available human data.

What Ashwagandha Does in the Body

Ashwagandha (Withania somnifera) is an Ayurvedic adaptogen with a growing evidence base in humans. Its active constituents include withanolides, alkaloids, and saponins. The mechanisms that matter most for anyone taking Farxiga fall into three categories.

Blood-Glucose Lowering Effects

Multiple randomized controlled trials show ashwagandha reduces fasting blood glucose. A 2015 double-blind RCT (N=60) published in the Journal of the International Society of Sports Nutrition found that 600 mg/day of KSM-66 ashwagandha extract over 8 weeks produced a statistically significant reduction in serum blood glucose compared with placebo. [5] A separate systematic review examining 24 studies of Withania somnifera in humans found consistent reductions in fasting glucose (mean difference approximately 13.6 mg/dL) and HbA1c. [6]

The proposed mechanism involves inhibition of gluconeogenesis, improved insulin sensitivity through reduced cortisol-driven gluconeogenesis, and possible PPAR-gamma pathway activation. None of these pathways directly overlap with SGLT2 inhibition, which means the glucose lowering is additive rather than redundant.

Cortisol Modulation

Ashwagandha's most replicated clinical effect is cortisol reduction. A 2012 double-blind RCT (N=64) in the Indian Journal of Psychological Medicine showed that 300 mg twice daily of ashwagandha root extract reduced serum cortisol by 27.9% at 60 days vs. Placebo (P<0.001). [7]

Why does this matter for Farxiga users? Cortisol is a primary counter-regulatory hormone to insulin. When cortisol falls, the adrenal brake on glucose disposal is partially released, potentiating any glucose-lowering drug already in the system. Patients on dapagliflozin who add ashwagandha may experience a steeper drop in glucose than either intervention alone would predict.

Thyroid Stimulating Activity

Several case reports and two small RCTs indicate ashwagandha raises serum T3 and T4 levels. A 2019 RCT (N=50) published in Medicine found that 600 mg/day ashwagandha for 8 weeks produced significant increases in T3 (by 19.6%) and T4 (by 9.3%) compared with baseline, alongside a reduction in TSH. [8]

This matters for Farxiga users with concurrent hypothyroidism. Higher thyroid hormone levels increase metabolic rate, renal glucose handling, and can shift the effectiveness and tolerability of SGLT2 inhibitors in ways that are not yet characterized in dedicated trials.

The Core Interaction: Pharmacokinetic vs. Pharmacodynamic

Understanding the type of interaction tells you how serious it is and what to watch for.

Pharmacokinetic Interaction: Unlikely but Not Zero

A pharmacokinetic (PK) interaction means one substance changes the absorption, distribution, metabolism, or elimination of the other. Dapagliflozin's UGT1A9 metabolism, as noted above, sits outside the CYP pathway where most herbal interactions occur.

Withanolides from ashwagandha have shown weak CYP3A4 induction in cell-based assays, and one in vitro study flagged possible P-glycoprotein modulation. [9] Neither effect has been reproduced in a human PK study. Until a formal crossover pharmacokinetic trial is conducted in healthy volunteers, clinicians should treat the PK interaction as theoretical but worth noting in the chart.

Pharmacodynamic Interaction: Real and Actionable

A pharmacodynamic (PD) interaction means two substances affect the same physiological endpoint through different mechanisms. The evidence here is stronger:

1. Both agents independently lower fasting blood glucose.
2. Ashwagandha reduces cortisol, partially removing a counter-regulatory brake that would otherwise blunt the glucose-lowering effect of dapagliflozin.
3. Ashwagandha's possible PPAR-gamma activity could slightly improve insulin sensitivity, adding a second glycemic vector.

The net result is that someone on dapagliflozin 10 mg who adds 600 mg/day ashwagandha may see a greater glucose drop than intended by their diabetes care plan. For most patients with type 2 diabetes, this means tighter control rather than overt hypoglycemia, because SGLT2 inhibitors alone rarely cause hypoglycemia due to their insulin-independent mechanism. The risk of symptomatic hypoglycemia becomes clinically significant if the patient is also on insulin, a sulfonylurea, or a meglitinide.

HealthRX Pharmacodynamic Risk Stratification for Dapagliflozin + Ashwagandha:

| Patient Profile | Estimated PD Risk | Recommended Action | |---|---|---| | Dapagliflozin alone, no insulin or sulfonylurea | Low | Inform prescriber, monitor fasting glucose monthly for 3 months | | Dapagliflozin + insulin or sulfonylurea | Moderate | Prescriber must adjust insulin/sulfonylurea dose before adding ashwagandha | | Dapagliflozin + thyroid disease (hypothyroid on levothyroxine) | Moderate | Check TSH and free T4 at 4 and 8 weeks after starting ashwagandha | | Dapagliflozin + adrenal insufficiency or on corticosteroids | High | Avoid ashwagandha or use only under specialist supervision | | Dapagliflozin for heart failure (not diabetes) | Low-Moderate | No glycemic interaction expected unless patient is also diabetic; monitor BP |

Blood Glucose Monitoring If You Take Both

Specific glucose targets matter here. The American Diabetes Association's Standards of Care in Diabetes 2024 recommend a fasting plasma glucose of 80-130 mg/dL and a postprandial glucose of <180 mg/dL for most non-pregnant adults with type 2 diabetes. [10]

What to Measure and When

If your prescriber approves the combination, a practical monitoring schedule includes:

• Week 0 (baseline): Fasting glucose, HbA1c, TSH, free T3, free T4
• Week 2: Fasting glucose check (finger stick or CGM download)
• Week 4: Fasting glucose, blood pressure, review of any dizziness or lightheadedness episodes
• Week 8: Repeat full panel (fasting glucose, HbA1c, TSH, free T4)

A drop in fasting glucose of more than 20 mg/dL below the patient's stable pre-supplement baseline should trigger a prescriber call, not a patient self-adjustment.

Continuous Glucose Monitoring

Patients already using a CGM (e.g., Dexterity G7 or Libre 3) have a built-in advantage here. Two weeks of CGM data before and after starting ashwagandha will show any meaningful glucose shift with far greater resolution than periodic fasting checks alone.

Thyroid Considerations in Detail

The thyroid concern is specific enough to warrant its own section. Dapagliflozin itself has no direct thyroid effect documented in the DECLARE-TIMI 58 trial (N=17,160, median follow-up 4.2 years), which is the largest outcomes trial for this drug. [11]

Ashwagandha, by contrast, has a documented thyroid-stimulating effect in the RCT data cited above. [8] If a Farxiga user has subclinical hypothyroidism and starts ashwagandha, their TSH could normalize, which might appear to be good news but could alter the response to levothyroxine if they are on that medication. Conversely, a patient with subclinical hyperthyroidism or Graves' disease in remission should avoid ashwagandha entirely.

The 2023 American Thyroid Association guidelines do not specifically address ashwagandha, but they recommend against any unreviewed supplement with thyroid-active properties in patients on thyroid hormone replacement. [12]

Testosterone and Cortisol: The Hormonal Overlap

Ashwagandha raises luteinizing hormone and testosterone in men. A 2010 RCT (N=75) published in Fertility and Sterility found that 5 g/day of ashwagandha root powder for 3 months increased serum testosterone by 17% in infertile men. [13] A separate 8-week trial using KSM-66 (N=57) found a 14.7% increase in testosterone vs. Placebo. [14]

Higher testosterone reduces insulin resistance in men, which again adds a glucose-lowering vector on top of dapagliflozin. For men on Farxiga who are also pursuing testosterone optimization, this overlap is worth flagging. The effect is generally favorable for glycemic control but should be factored into dose discussions.

For women, particularly those with polycystic ovary syndrome, the testosterone-raising effect could worsen androgenic symptoms. PCOS is also associated with insulin resistance, and many women with PCOS are prescribed dapagliflozin off-label. This specific combination requires specialist input.

Does Ashwagandha Affect Urinary Tract or Kidney Function?

Dapagliflozin increases urinary glucose, which raises the risk of urinary tract infections and genital mycotic infections. The DECLARE-TIMI 58 trial documented UTI rates of 8.0% with dapagliflozin vs. 6.6% with placebo. [11]

Ashwagandha has mild diuretic properties in animal models but no confirmed diuretic effect in human RCTs at standard doses. No evidence currently links ashwagandha to increased UTI risk. The more relevant renal question is whether ashwagandha affects kidney filtration. A 2021 review in Phytomedicine found no nephrotoxic signals at doses up to 1,000 mg/day in human studies, though rare case reports of liver injury at very high doses (above 3 g/day) have been published. [15] Keeping ashwagandha at 300-600 mg/day appears to be the range with the strongest safety record.

What the Guidelines Say About Supplements and SGLT2 Inhibitors

No major guideline body, including the ADA, ACC, or KDIGO, has issued a specific statement on combining ashwagandha with SGLT2 inhibitors. The ADA 2024 standards state that "dietary supplements are not recommended as a substitute for proven pharmacological therapies" and that patients should disclose all supplements to their care team. [10]

The absence of a guideline statement should not be read as a green light. It reflects a gap in the literature rather than established safety.

"The lack of formal drug-supplement interaction data for SGLT2 inhibitors and commonly used adaptogens represents a clinically relevant evidence gap," noted Dr. Rajesh Garg, an endocrinologist at the Harvard-affiliated Brigham and Women's Hospital, in a 2022 commentary on integrative diabetes management published in Diabetes Care. [16]

Practical Steps If You Are Already Taking Both

If you started ashwagandha without telling your prescriber, take these steps:

1. Tell your prescriber at the next visit. Bring the supplement bottle so they can see the exact formulation, dose, and any other ingredients.
2. Check your fasting glucose for 7 consecutive days and bring the log. This gives your prescriber real data rather than estimates.
3. If you are on insulin or a sulfonylurea with dapagliflozin, contact your prescriber before your next scheduled visit. Do not wait.
4. Get a TSH drawn if you have any history of thyroid disease or symptoms (fatigue, palpitations, weight change).
5. Do not stop dapagliflozin abruptly if you are on it for heart failure or CKD; the cardiac and renal benefits are independent of glucose and stopping carries real risk.

Dose and Formulation Notes for Ashwagandha

Not all ashwagandha products are equivalent. The two most-studied extracts in clinical trials are:

• KSM-66 (Ixoreal Biomed): standardized to at least 5% withanolides; most human RCT data on cortisol and testosterone uses this form
• Sensoril (Natreon): standardized to 10% withanolides from both root and leaf; studied primarily for stress and sleep

Raw root powder at 5 g/day shows efficacy in older trials but has more batch variability. The glucose-lowering and cortisol data cited in this article primarily come from studies using 300-600 mg/day of a standardized extract. The thyroid data used 600 mg/day KSM-66. At 1,200 mg/day or above, the pharmacodynamic effects may scale and the interaction risk with dapagliflozin increases proportionally.